Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Debt (2023 - 2025)

China SXT Pharmaceuticals (SXTC) has 3 years of Non-Current Debt data on record, last reported at $96264.0 in Q1 2025.

  • For Q1 2025, Non-Current Debt fell 17.81% year-over-year to $96264.0; the TTM value through Mar 2025 reached $96264.0, down 17.81%, while the annual FY2025 figure was $96264.0, 17.81% down from the prior year.
  • Non-Current Debt reached $96264.0 in Q1 2025 per SXTC's latest filing, down from $117129.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $117862.0 in Q1 2023 and bottomed at $96264.0 in Q1 2025.
  • Average Non-Current Debt over 3 years is $110418.3, with a median of $117129.0 recorded in 2024.
  • Peak YoY movement for Non-Current Debt: dropped 0.62% in 2024, then decreased 17.81% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $117862.0 in 2023, then fell by 0.62% to $117129.0 in 2024, then dropped by 17.81% to $96264.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $96264.0 in Q1 2025, $117129.0 in Q1 2024, and $117862.0 in Q1 2023.